Actinium Pharmaceuticals (NYSE: ATNM) Showcases Approx. 15% Early Move as Major Collaboration Hits the Wire

*Sponsored Krypton Street Initiates Coverage On Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Starting This Morning—3/20/2025. Here’s Why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Is Topping Our Watchlist Right Now… Analyst Backing: Multiple Wall Street Firms Have Issued Bullish Targets, With Some Projecting Up To 313% Upside Potential As Attention Grows. Building Momentum: Shares Have Moved Approximately 26% In 10 Sessions, Surpassing Key Moving Averages And Signaling Growing Interest. Still Under The Radar: With A Market Cap Under $40M And A Float Below 32M Shares, This Structure Has Historically Shown Higher Growth Potential. Upcoming Clinical Data: Key Proof-Of-Concept Trials Evaluating Its Targeted Radiotherapy With PD-1 Inhibitors Are Expected By Late 2025. Strong Intellectual Property: Hundreds Of Patents, Including Exclusive Rights To Actinium-225 Production, Reinforce Its Leadership In Radiotherapy Innovation. Take A Look At Actinium Pharmaceuticals, Inc. (NYSE: ATNM)  While It’s Still Early. March 20, 2025 Dear Reader, A new research collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) just hit the wire, expanding the potential of Actimab-A as a backbone therapy.  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will now explore FLT3 and menin inhibitors while testing Actimab-A’s effectiveness in AML patients—including those who have failed standard treatments. Meanwhile, (ATNM) moved approximately 15% in the early session from $1.19 to $1.38, Triggering Multiple Bullish Signals on TradingView’s technical analysis tool and surpassing key moving averages. With Phase 2/3 trials moving forward and new studies targeting solid tumors, this latest development could be a pivotal step forward for Actinium Pharmaceuticals, Inc. (NYSE: ATNM).  If you missed my earlier coverage, keep reading to see why we’re so excited about  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) right now. Some of the most important developments in medicine start quietly before they gain widespread recognition. This company has been advancing a radiotherapy approach designed to work alongside established treatments.  Now, as new developments unfold, Wall Street analysts have begun adjusting their targets accordingly. We’re keeping a close eye on Actinium Pharmaceuticals, Inc. (NYSE: ATNM) this morning—here’s what you need to know. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Shows Strong  Momentum Potential Over 10 Sessions… In just 10 recent sessions, ATNM has moved approximately 26%, from $1.02 on 3/4/2025 to $1.30 on 3/17/2025. This upward move has pushed ATNM past key technical levels, as highlighted by Barchart: -5-Day Moving Average: $1.22 -20-Day Moving Average: $1.1595 -50-Day Moving Average: $1.2044 With its 100-Day and 200-Day moving averages at $1.3424 and $2.8559, respectively, we have all eyes on Actinium Pharmaceuticals, Inc. (NYSE: ATNM) this morning. But this is where it gets interesting… Analyst Target Suggests Over 331% Upside Potential… Wall Street analysts have begun recognizing Actinium Pharmaceuticals, Inc. (NYSE: ATNM)’s potential, with multiple firms issuing strong targets: -Maxim Group: Analyst Jason McCarthy, Ph.D., has a $5 target that was published in a March 14, 2025 report, which suggests a 331% upside potential move from today’s $1.16 range . -HC Wainwright & Co.: Senior Healthcare Analyst Joseph Pantginis, Ph.D., reaffirmed a $4 target, as reported by Benzinga, which suggests 244% upside potential. -Stephens, Inc.: Analyst Sudan Loganathan, Ph.D., maintained an "Overweight" rating with a $5 target. Big names may dominate the headlines, but it’s the small and micro-cap companies flying under the radar that often make the biggest moves when the right catalyst hits. With a market cap under $40M and fewer than 32M shares in the float, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) operates with the kind of tight structure that has historically fueled rapid growth when momentum builds.  Now, with analysts setting targets as high as $5, signaling potential upsides of 244% to 331%, this under-the-radar biotech may not stay unnoticed for long. Keep reading to see why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is topping our watchlist this morning. About Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a pioneer in targeted radiotherapy for oncology.  The company is advancing Actimab-A, a CD33-targeting therapeutic designed as a backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies.  Actimab-A leverages Actinium-225 (Ac-225), a mutation-agnostic alpha-emitter radioisotope, to deliver targeted radiotherapy directly to cancer cells. Key Developments: -Actimab-A has shown high rates of Complete Remission (CR) and measurable residual disease (MRD) negativity in relapsed and refractory AML (r/r AML) patients. -The candidate is advancing to a pivotal Phase 2/3 clinical trial, with potential implications for significantly improved patient outcomes. -Actinium is working with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) to expand Actimab-A’s applications. Beyond AML, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is also developing Actimab-A as a combination therapy for solid tumors, particularly in combination with PD-1 checkpoint inhibitors, such as: -KEYTRUDA® (Merck & Co.) -OPDIVO® (Bristol Myers Squibb) Breakthrough Potential in the Immuno-Oncology Market Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is launching clinical trials to evaluate Actimab-A in combination with PD-1 inhibitors for solid tumors.  The goal is to address Myeloid-Derived Suppressor Cells (MDSCs), which reduce the effectiveness of treatments like KEYTRUDA® and OPDIVO®.  Actimab-A targets and depletes CD33-expressing MDSCs, potentially enhancing PD-1 therapies and expanding immuno-oncology applications. Ongoing trials will compare Actimab-A + KEYTRUDA® vs. KEYTRUDA® alone and Actimab-A + OPDIVO® vs. OPDIVO® alone, focusing on Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-Small Cell Lung Cancer (NSCLC).  These studies will measure Overall Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), and MDSC depletion patterns. Initial proof-of-concept clinical data is expected in late 2025, potentially marking a major milestone for Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Actinium Pharmaceuticals (NYSE: ATNM): Advancing the Next Generation of Targeted Radiotherapy Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is advancing a targeted radiotherapy platform centered around Actinium-225 (Ac-225)—a cutting-edge approach designed to enhance precision treatment. With a strong intellectual property portfolio and a growing clinical pipeline, it’s positioning itself as a leader in the space. Here’s what stands out: -230 Patents & Exclusive Protections – The company holds critical intellectual property rights related to the production of Ac-225 in a cyclotron, securing its place in targeted radiotherapy. -Pipeline of Targeted Therapies – Actimab-A, its lead program, is designed for acute myeloid leukemia (AML), with ongoing trials assessing its use in combination with PD-1 inhibitors for solid tumors. -Iomab-B Advancing Toward Commercialization – Being developed as an induction and conditioning agent for bone marrow transplants in relapsed/refractory AML, with Actinium actively seeking a U.S. commercialization partner. -Addressing Treatment Resistance – Actimab-A is being tested alongside PD-1 inhibitors to target Myeloid-Derived Suppressor Cells (MDSCs)—a factor in treatment resistance for many solid tumors. -Large Potential Patient Population – The company is focusing on hundreds of thousands of patients affected by MDSC-driven tumor resistance, a key area of interest for novel treatment combinations. -Encouraging Preclinical Data – Early studies suggest Actimab-A’s novel mechanism could address unmet medical needs in patients whose cancers stop responding to PD-1 therapies. With a strong foundation in radiotherapy innovation, a growing clinical pipeline, and increasing attention from analysts, several key factors make Actinium Pharmaceuticals, Inc. (NYSE: ATNM) a name to watch right now. Here’s 5 Quick Reasons Why Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Has Our Attention Early This Morning… 1. Analyst Backing: Wall Street firms have issued bullish targets on Actinium Pharmaceuticals, Inc. (NYSE: ATNM), with some projecting up to 313% upside potential as attention grows. 2. Building Momentum: In just 10 sessions, shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have moved approximately 26%, surpassing key moving averages and signaling growing interest. 3. Still Under the Radar: Despite a market cap under $40M and a float below 32M shares, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has a structure that has historically shown higher growth potential. 4. Upcoming Clinical Data: Key proof-of-concept trials for Actinium Pharmaceuticals, Inc. (NYSE: ATNM) evaluating its targeted radiotherapy with PD-1 inhibitors are expected by late 2025. 5. Strong Intellectual Property: With hundreds of patents, including exclusive rights to Actinium-225 production, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has reinforced its leadership in radiotherapy innovation. Put Actinium Pharmaceuticals, Inc. (NYSE: ATNM) On Your  Radar This Morning… Not every name makes our watchlist, but Actinium Pharmaceuticals, Inc. (NYSE: ATNM)’s momentum is hard to ignore. With an approximate 26% move in recent sessions, multiple analysts setting bold targets, and key clinical data ahead, this under-the-radar company is gaining traction. Its patent portfolio, institutional collaborations, and market structure only add to the case. We have all eyes on (ANTM) right now.  Actinium Pharmaceuticals, Inc. (NYSE: ATNM) moved approximately 15% in the early session from $1.19 to $1.38, Triggering Multiple Bullish Signals. Are you watching this yet? Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/20/2025 and ending on 03/20/2025 to publicly disseminate information about (ATNM:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (ATNM:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/atnm/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice